Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
15 hedge funds and large institutions have $347K invested in Evofem Biosciences, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
6% less funds holding
Funds holding: 16 → 15 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
38% less capital invested
Capital invested by funds: $561K → $347K (-$214K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$542K |
| 2 |
Renaissance Technologies
New York
|
+$88.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.6K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$72.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$36.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$145K |
| 2 |
FPF
FNY Partners Fund
New York
|
-$37K |
| 3 |
Millennium Management
New York
|
-$18K |
| 4 |
Goldman Sachs
New York
|
-$17.9K |
| 5 |
Morgan Stanley
New York
|
-$8K |
EVFM Hedge Fund Activity: Q2 2017 in Review
15 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2017, worth a combined $347K — down 38% from $561K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EVFM and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $542K. The largest seller was UBS AM, exiting entirely with an estimated $145K sold.
- 15 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2017, down from 16 in Q1 2017.
- Funds reported $347K of Evofem Biosciences, Inc. Common Stock stock for Q2 2017, down 38% quarter-over-quarter.
- 3 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2017 and 4 closed out, a net change of -1 holder.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2017 was Virtu KCG Holdings, an estimated $542K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2017 was UBS AM, an estimated $145K sold.
Based on aggregated 13F filings for Q2 2017.